Clinical Trial Finder

DISEASE CHARACTERISTICS:

• - Diagnosis of 1 of the following: - Histologically confirmed supratentorial malignant primary glioma.

• - Glioblastoma multiforme.

• - Anaplastic astrocytoma.

• - Anaplastic oligodendroglioma.

• - Anaplastic mixed oligoastrocytoma.

• - Malignant astrocytoma not otherwise specified.

• - Histologically confirmed or radiographically defined recurrent or progressive brain or spinal meningioma, including base of skull or cavernous sinus meningiomas.

• - Benign, malignant, or atypical.

• - May include neurofibromatosis type I or II.

• - Hemangiopericytoma allowed.

• - Recurrent or progressive disease by MRI or CT scan.

• - Evidence of true progressive disease by PET or thallium scan, MR spectroscopy, or surgical documentation required if patient received prior interstitial brachytherapy or stereotactic radiosurgery (to the target lesion for meningioma and hemangiopericytoma) - Steroid dosage must be stable for at least 5 days prior to scan.

• - No limitations on the number of prior surgeries, radiotherapy or chemotherapy regimens, or radiosurgery treatments for patients with meningioma or hemangiopericytoma and may include standard external beam radiotherapy, interstitial brachytherapy, or gamma-knife radiosurgery in any combination.

• - Patients with glioma must have failed prior radiotherapy.

• - Original histology of low-grade glioma allowed if subsequent confirmation of malignant glioma is made at time of recurrence.

• - Phase I (closed to accrual as of 09/19/2003): - Prior treatment for no more than 3 prior relapses in patients with glioma.

• - Phase II: - Measurable disease after prior surgical resection of recurrent or progressive disease.

• - Prior treatment for no more than 2 prior relapses in patients with glioma.

PATIENT CHARACTERISTICS: Age:

• - 18 and over.

Performance status:

• - Karnofsky 60-100% Life expectancy: - More than 8 weeks.

Hematopoietic:

• - WBC at least 3,000/mm^3.

• - Absolute neutrophil count at least 1,500/mm^3.

• - Platelet count at least 120,000/mm^3.

• - Hemoglobin at least 10 g/dL (transfusion allowed) Hepatic: - Bilirubin less than 1.5 times upper limit of normal (ULN) - SGOT less than 1.5 times ULN.

Renal:

• - Creatinine less than 1.5 mg/dL OR.

• - Creatinine clearance at least 60 mL/min.

Cardiovascular:

• - No significant cardiac risk factors within the past 6 months.

Other:

• - Not pregnant or nursing.

• - Negative pregnancy test.

• - Fertile patients must use effective contraception.

• - No gastrointestinal risk factors (e.g., active ulcerative colitis) within the past 6 months.

• - No active infection.

• - No concurrent disease that would obscure toxicity or dangerously alter drug metabolism.

• - No other significant medical illness that would preclude study.

• - No other malignancy within the past 3 years except non-melanoma skin cancer or carcinoma in situ of the cervix.

PRIOR CONCURRENT THERAPY: Biologic therapy:

• - At least 1 week since prior interferon or thalidomide.

• - No concurrent filgrastim (G-CSF) Chemotherapy: - See Disease Characteristics.

• - At least 2 weeks since prior vincristine.

• - At least 6 weeks since prior nitrosoureas.

• - At least 3 weeks since prior procarbazine.

Endocrine therapy:

• - At least 1 week since prior tamoxifen.

Radiotherapy:

• - See Disease Characteristics.

• - At least 4 weeks since prior radiotherapy.

Surgery:

• - See Disease Characteristics.

• - At least 7 days since prior surgery for recurrent or progressive tumor and recovered.

Other:

• - Recovered from prior therapy.

• - No prior gefitinib or other epidermal growth factor receptor inhibitor.

• - At least 1 week since prior isotretinoin.

• - At least 1 week since other prior noncytotoxic agents (except radiosensitizers) - At least 4 weeks since prior investigational agents.

- Concurrent low-molecular weight heparin or warfarin for deep vein thrombosis or pulmonary embolism allowed

OBJECTIVES:

• - Determine the maximum tolerated dose of gefitinib in patients with recurrent or progressive supratentorial malignant gliomas or brain or spinal meningiomas receiving enzyme-inducing antiepileptic drugs (EIAEDs).

(Phase I of the study closed to accrual as of 09/19/2003).

• - Determine the toxic effects of this drug in these patients.

• - Determine the pharmacokinetics of this drug in patients receiving EIAEDs.

• - Determine the efficacy of this drug in terms of 6-month progression-free survival of these patients.

• - Determine the safety profile of the phase II dose of this drug in these patients.

OUTLINE: This is a multicenter, dose-escalation study. Patients are stratified according to concurrent enzyme-inducing antiepileptic drugs (EIAEDs) (yes vs.#46;no) and disease type (for phase II only) (benign meningioma vs.#46;malignant meningioma vs.#46;hemangiopericytoma vs.#46; glioblastoma vs.#46;other anaplastic glioma). (Phase I closed to accrual as of 09/19/2003). Patients receive oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients (who are receiving EIAEDs) receive escalating doses of gefitinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients are followed at 2 weeks. PROJECTED ACCRUAL: A minimum of 30 patients will be accrued for the phase I portion of this study within 10 months . (Phase I closed to accrual as of 09/19/2003). A total of 48 patients will be accrued for the phase II portion of this study within 6-8 months.

Arms

Active Comparator: p450

p450 inhibitor

Active Comparator: nonp450

not on p450 inhibitor

Interventions

Drug: - gefitinib